Original Mounjaro KwikPen Tirzepatide 15mg/0.6ml, Four-Dose Pre-Filled Injection Pen For Subcutaneous Injection

Mounjaro® (tirzepatide injection) is a once-weekly prescription medicine designed to improve blood sugar control in adults with type 2 diabetes. It is used alongside a healthy diet and regular exercise and represents a new generation of treatment that targets two important hormone pathways to help regulate glucose and support weight management.

How Mounjaro® Works

Mounjaro® is a dual GIP and GLP-1 receptor agonist. This means it activates two incretin hormones:

• GIP (glucose-dependent insulinotropic polypeptide)

• GLP-1 (glucagon-like peptide-1)

By acting on both, Mounjaro® helps the body:

• Release more insulin when blood sugar is high

• Reduce the amount of glucagon, a hormone that raises blood sugar

• Slow down stomach emptying, which may reduce appetite

This dual action provides powerful effects on blood sugar control and weight reduction.

Dosage Forms and Strengths

Mounjaro® is supplied as a clear, colorless to slightly yellow solution for subcutaneous injection.

• Single-Dose Prefilled Pen or Vial:

  • 2.5 mg / 0.5 mL

  • 5 mg / 0.5 mL

  • 7.5 mg / 0.5 mL

  • 10 mg / 0.5 mL

  • 12.5 mg / 0.5 mL

  • 15 mg / 0.5 mL

• Mounjaro® KwikPen® (Multi-Dose Prefilled Pen):

  • Contains 4 fixed doses per pen

  • Available in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg strengths (each in 0.6 mL solution)

Recommended Dosing

• Starting Dose: 2.5 mg once weekly for 4 weeks

• Step-Up Schedule: Increase to 5 mg once weekly; if needed, increase in 2.5 mg increments after at least 4 weeks on the current dose

• Maximum Dose: 15 mg once weekly

Administration Guidelines:

• Inject subcutaneously into abdomen, thigh, or upper arm

• Rotate injection sites weekly

• Can be given with or without meals at any time of the day

• Do not administer daily, intramuscularly, or intravenously

Safety Information & Warnings

• Thyroid C-Cell Tumors
  Tirzepatide has caused thyroid tumors in animal studies. The risk in humans is unknown.

  • Do not use if you or a family member has a history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

• Pancreatitis
  Cases of acute pancreatitis have been reported. Discontinue immediately if severe abdominal pain occurs.

• Hypoglycemia
  Low blood sugar may occur when used with insulin or sulfonylureas. Dose adjustments may be required.

• Gastrointestinal Side Effects
  Nausea, vomiting, diarrhea, and constipation are common. Severe cases may cause dehydration and kidney complications.

• Pregnancy and Breastfeeding
  Contraindicated during pregnancy and breastfeeding. Women of childbearing age should use effective contraception during treatment and for at least 1 month after the last dose. Oral contraceptives may be less effective, so use a barrier or non-oral method during dose escalation.

Common Side Effects

The most frequently reported side effects are gastrointestinal and are usually mild to moderate:

• Nausea

• Diarrhea

• Vomiting

• Decreased appetite

• Constipation

• Indigestion (dyspepsia)

• Abdominal pain

Storage Instructions

• Store in a refrigerator (2°C – 8°C / 36°F – 46°F)

• Do not freeze

• Once opened, a pen may be kept at room temperature (up to 30°C) for up to 30 days